Skip to main content
OpenTrials
Completed

NCT Number: NCT02742077

Robotic-Assisted Peripheral Intervention for Peripheral Arterial Disease II

The purpose of this study is to evaluate the safety and performance of the CorPath 200 System in the remote delivery and manipulation of guidewires and rapid exchange catheters for use in percutaneous vascular interventions.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Medizinische Univeristät Graz

Graz, A-8036, Austria

About this study

This is a prospective, single-arm, single center, non-randomized feasibility study of the CorPath 200 System to examine its performance during complete interventions (DCB, Stenting) of the femoropopliteal arteries and patient outcomes at 30 days.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

General Inclusion Criteria

  • At least 18 years of age;
  • Symptomatic disease: presence of critical limb ischemia (including tissue loss or rest pain), or lifestyle-limiting claudication requiring intervention in the femoropopliteal arteries; and
  • The subject has been informed of the nature of the study and agrees to its provisions and has provided written informed consent.

Angiographic Inclusion Criteria Femoropopliteal artery lesion(s) with stenosis (>50%) or occlusion of up to 120 mm in length as determined by imaging (MRA or Angio) prior to index interventional procedure.

Exclusion criteria

General Exclusion Criteria

If any of the following criteria are met, the subject cannot be enrolled in this study:

  • Failure/inability/unwillingness to provide informed consent;
  • Target vessel has been previously treated with bypass; or
  • Enrolled in concurrent clinical study.

Angiographic Exclusion Criteria

  • Target vessel:
  • Shows evidence of previous dissection or perforation, or
  • Has adjacent acute thrombus; or
  • Has a pre-existing target artery aneurysm or perforation or dissection of the target artery prior to initiation of the interventional procedure.

Treatment and study plan

Robotic-assisted peripheral vascular intervention

Device

Remote delivery and manipulation of guidewires and rapid exchange catheters during percutaneous vascular interventions.

Primary outcomes

  1. Clinical Success

    Time frame: 72 hours or hospital discharge, whichever comes first.

    Defined as <50% residual stenosis in all CorPath 200 System treated lesions at the completion of the interventional procedure in the absence of device-related serious adverse events (SAE).

  2. Adverse Events

    Time frame: Procedure

    No device-related serious adverse events.

Secondary outcomes

  1. Operator Radiation Exposure Dose

    Time frame: Procedure

    Physician operator radiation exposure as recorded on personal Enterprise Dose Dashboard (EDD; Landauer) dosimeters

  2. Patient Radiation Exposure Dose

    Time frame: Procedure

    Patient Radiation Dose-area-product (DAP)

Sponsors and collaborators

Lead sponsor

Siemens Healthineers Endovascular Robotics, Inc.

Industry

Registry information

Official study title

CorPath® 200 RAPID II Study (Robotic-Assisted Peripheral Intervention for Peripheral Arterial Disease)

Acronym: RAPID II

Important dates

Study start
2016
Primary completion
2016
Study completion
2016
First posted
Apr 18, 2016
Registry last updated
Nov 4, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.